1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0240, GOG-0240, NCT00803062
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CINJ-100101, NJ 1703, CINJ-3390, CINJ-NJ1703, NCT00138151
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 03-33, NCT00257816
|
|
5.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
6.
|
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UW-6143, UW IRB# 6143, 7958, NCT00559377
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-1098, GSK 107278, NCT00548418
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2007-0324, NCT00626561
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709
|
|
10.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM104-B-001-09, NCT00900562
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI
Protocol IDs: 090037, 09-C-0037, NCT00924066
|
|
13.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 803776, UPCC 03505, NCT00299962
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 05C.255, NCT00329589
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06C.549, NCT00437372
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MI-CP177, NCT00796055
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ATDTRPST0802, NCT00800345
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ATDTCC0801, NCT00967928
|
|
20.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TAMC 3H04, NCT00160472
|
|
21.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2003-0529, NCT00394602
|
|
22.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0962, NCT00415675
|
|
23.
|
Phase: No phase specified
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: HM10390, P01CA116602, NCT00571415
|
|
24.
|
Phase: No phase specified
Type: Health services research, Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 08-092, NCT00746018
|
|
25.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-08992, 08992, H10778-32056, NCT00911079
|
